These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29337157)

  • 1. Update on the Use of Vonoprazan: A Competitive Acid Blocker.
    Graham DY; Dore MP
    Gastroenterology; 2018 Feb; 154(3):462-466. PubMed ID: 29337157
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
    Kiyotoki S; Nishikawa J; Sakaida I
    Intern Med; 2020 Jan; 59(2):153-161. PubMed ID: 31243237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
    Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
    J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vonoprazan fumarate for the management of acid-related diseases.
    Martinucci I; Blandizzi C; Bodini G; Marabotto E; Savarino V; Marchi S; de Bortoli N; Savarino E
    Expert Opin Pharmacother; 2017 Aug; 18(11):1145-1152. PubMed ID: 28657473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
    Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
    Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.
    Kusano C; Gotoda T; Suzuki S; Ikehara H; Moriyama M
    J Gastroenterol; 2018 Jun; 53(6):718-724. PubMed ID: 29110085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication.
    Kusunoki M; Yuki M; Ishitobi H; Kobayashi Y; Nagaoka M; Takahashi Y; Fukuba N; Komazawa Y; Shizuku T; Kinoshita Y
    Intern Med; 2019 Jun; 58(11):1549-1555. PubMed ID: 30713328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
    Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
    Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.
    Sakurai Y; Shiino M; Okamoto H; Nishimura A; Nakamura K; Hasegawa S
    Adv Ther; 2016 Sep; 33(9):1519-35. PubMed ID: 27432383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
    Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on quinolone-containing rescue therapies for
    Mori H; Suzuki H
    World J Gastroenterol; 2020 Apr; 26(15):1733-1744. PubMed ID: 32351290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection.
    Shinmura T; Adachi K; Yamaguchi Y; Izawa S; Hijikata Y; Ebi M; Funaki Y; Ogasawara N; Sasaki M; Kasugai K
    J Gastrointestin Liver Dis; 2019 Dec; 28(4):389-395. PubMed ID: 31826057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.
    Matsumoto H; Shiotani A; Katsumata R; Fujita M; Nakato R; Murao T; Ishii M; Kamada T; Haruma K; Graham DY
    Dig Dis Sci; 2016 Nov; 61(11):3215-3220. PubMed ID: 27659671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
    Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
    Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin.
    Takara Y; Endo H; Nakano R; Kawachi K; Hidaka H; Matsunaga T; Tsuruoka N; Sakata Y; Shimoda R; Hara M; Fujimoto K
    Digestion; 2019; 99(2):172-178. PubMed ID: 30179876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
    Jung YS; Kim EH; Park CH
    Aliment Pharmacol Ther; 2017 Jul; 46(2):106-114. PubMed ID: 28497487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori.
    Shinozaki S; Nomoto H; Kondo Y; Sakamoto H; Hayashi Y; Yamamoto H; Lefor AK; Osawa H
    Kaohsiung J Med Sci; 2016 May; 32(5):255-60. PubMed ID: 27316584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
    Suzuki S; Gotoda T; Kusano C; Iwatsuka K; Moriyama M
    Am J Gastroenterol; 2016 Jul; 111(7):949-56. PubMed ID: 27185079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Current Role of Vonoprazan in Helicobacter pylori Treatment.
    Fallone CA
    Gastroenterology; 2022 Sep; 163(3):572-574. PubMed ID: 35780869
    [No Abstract]   [Full Text] [Related]  

  • 20. Drugs for Helicobacter pylori infection.
    Med Lett Drugs Ther; 2017 Jul; 59(1525):113-117. PubMed ID: 28699931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.